EU drugs regulator rejects Lilly’s Alzheimer’s drug – POLITICO
In a Phase 3 trial involving 1,700 people, Kisunla slowed cognitive decline by up to 35 percent in…
In a Phase 3 trial involving 1,700 people, Kisunla slowed cognitive decline by up to 35 percent in…
It found that one in six people in the region die before their 70th birthday from non-communicable diseases…